InflaRx Stock Forecast, Price & News

InflaRx (NASDAQ:IFRX) Frequently Asked Questions

Is InflaRx a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for InflaRx in the last twelve months. There are currently 1 sell rating, 3 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" InflaRx stock.
View analyst ratings for InflaRx or view top-rated stocks.

How has InflaRx's stock been impacted by Coronavirus (COVID-19)?

InflaRx's stock was trading at $3.23 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, IFRX shares have increased by 27.2% and is now trading at $4.11.
View which stocks have been most impacted by COVID-19.

Are investors shorting InflaRx?

InflaRx saw a decrease in short interest in the month of November. As of November 15th, there was short interest totaling 666,800 shares, a decrease of 23.2% from the October 31st total of 868,200 shares. Based on an average daily volume of 2,980,000 shares, the short-interest ratio is presently 0.2 days. Currently, 1.8% of the company's shares are sold short.
View InflaRx's Short Interest.

When is InflaRx's next earnings date?

InflaRx is scheduled to release its next quarterly earnings announcement on Thursday, March 24th 2022.
View our earnings forecast for InflaRx.

How were InflaRx's earnings last quarter?

InflaRx (NASDAQ:IFRX) issued its earnings results on Wednesday, May, 12th. The company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.05.
View InflaRx's earnings history.

What price target have analysts set for IFRX?

5 brokerages have issued twelve-month price objectives for InflaRx's shares. Their forecasts range from $2.50 to $16.00. On average, they anticipate InflaRx's stock price to reach $9.90 in the next year. This suggests a possible upside of 140.9% from the stock's current price.
View analysts' price targets for InflaRx or view top-rated stocks among Wall Street analysts.

Who are InflaRx's key executives?

InflaRx's management team includes the following people:

• Niels Christoph Riedemann, Chief Executive Officer & Executive Director
• Thomas Taapken, Chief Financial Officer
• Renfeng Guo, Executive Director & Chief Scientific Officer
• Maria Habel, Head-Research & Development
• Korinna Pilz, Chief Clinical Development Officer

Who are some of InflaRx's key competitors?

Some companies that are related to InflaRx include ADVANZ PHARMA (CXRXF), Kiniksa Pharmaceuticals (KNSA), Phibro Animal Health (PAHC), Praxis Precision Medicines (PRAX), Edgewise Therapeutics (EWTX), Arcutis Biotherapeutics (ARQT), Syndax Pharmaceuticals (SNDX), CytoDyn (CYDY), Aclaris Therapeutics (ACRS), Celularity (CELU), Silence Therapeutics (SLN), Precigen (PGEN), Imago BioSciences (IMGO), Northwest Biotherapeutics (NWBO) and Stoke Therapeutics (STOK).
View all of IFRX's competitors.

What other stocks do shareholders of InflaRx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other InflaRx investors own include Dynavax Technologies (DVAX), Gilead Sciences (GILD), ImmunoGen (IMGN), Inovio Pharmaceuticals (INO), AbbVie (ABBV), OPKO Health (OPK), Capricor Therapeutics (CAPR), Citius Pharmaceuticals (CTXR), (KDMN) and Moderna (MRNA).

When did InflaRx IPO?

(IFRX) raised $100 million in an initial public offering on Wednesday, November 8th 2017. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO.

What is InflaRx's stock symbol?

InflaRx trades on the NASDAQ under the ticker symbol "IFRX."

Who are InflaRx's major shareholders?

InflaRx's stock is owned by a number of retail and institutional investors. Top institutional investors include Morgan Stanley (1.67%), Great Point Partners LLC (1.28%), FNY Investment Advisers LLC (0.74%), Renaissance Technologies LLC (0.19%), Millennium Management LLC (0.11%) and Two Sigma Securities LLC (0.05%).

Which institutional investors are selling InflaRx stock?

IFRX stock was sold by a variety of institutional investors in the last quarter, including Great Point Partners LLC, Renaissance Technologies LLC, Morgan Stanley, FNY Investment Advisers LLC, Raymond James & Associates, and Raymond James Financial Services Advisors Inc..

Which institutional investors are buying InflaRx stock?

IFRX stock was acquired by a variety of institutional investors in the last quarter, including Two Sigma Securities LLC, Geode Capital Management LLC, Millennium Management LLC, and Two Sigma Investments LP.

How do I buy shares of InflaRx?

Shares of IFRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is InflaRx's stock price today?

One share of IFRX stock can currently be purchased for approximately $4.11.

How much money does InflaRx make?

InflaRx has a market capitalization of $177.68 million. The company earns $-38.82 million in net income (profit) each year or ($1.32) on an earnings per share basis.

How many employees does InflaRx have?

InflaRx employs 49 workers across the globe.

What is InflaRx's official website?

The official website for InflaRx is www.inflarx.de.

Where are InflaRx's headquarters?

InflaRx is headquartered at WINZERLAER STR. 2, JENA 2M, 07745.

How can I contact InflaRx?

InflaRx's mailing address is WINZERLAER STR. 2, JENA 2M, 07745. The company can be reached via phone at 493641508180 or via email at [email protected].